Jeff Jonker, CEO of Belharra Therapeutics, discusses the renaissance in small molecule drug discovery. Topics include their accidental entry into biotech, the significance of building relationships in the industry, the appeal of sustainable platform companies, chemo proteomics, small molecule binders and covalent bonds in drug discovery, and covalent and non-covalent binding in small molecule drug discovery.

Nancy Stagliano, CEO of Neuron23, discusses precision medicine in neuroscience drug discovery. Topics include genetic underpinnings of Parkinson's, studying neurodegeneration, transitioning from academia to biotech, challenges in drug discovery, focusing on Alzheimer's lead program, genetic links to neurological disorders, and future of targeted treatments.

Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.

Reid Huber, partner at Third Rock Ventures, discusses investing in the future of medicine. The podcast covers his journey from genetics to drug discovery, reflections on a long-term career, transitioning into venture capitalism, navigating the stock market and legislation impact, and revolutionizing medical oncology through clinical trials and innovation.

Jeff Huber, co-founder and general partner at Triatomic Capital, shares his career journey from tech to biotech. He discusses early cancer detection, using computers to enhance business processes, approaches to cancer treatment, and the development of a new cancer screening method. The chapter also examines the acquisition of Grail by Illumina and the regulatory challenges. Jeff also shares his inspiring adventure in Everest Base Camp and highlights the progress and impact in the biotech industry.

Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.

Turning the Tables, Rob Perez Interviews Me

Explore the journey of Curie.Bio founders Zach Weinberg and Alexis Borisy in empowering biotech entrepreneurs. Learn about the hands-on support offered to founders, the evolution of Flatiron Health, and the collaborative approach of Curie Bio in prioritizing founder ownership and control in the biotech industry.

Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.

Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.